Journal
FUTURE ONCOLOGY
Volume 16, Issue 32, Pages 2661-2672Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-0234
Keywords
aromatase inhibitor; CDK4; 6 inhibitors; faslodex; hormone-receptor positive; metastatic breast cancer
Categories
Ask authors/readers for more resources
There are three US FDA-approved CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib for patients with HR-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC). They are all equally effective, so the question becomes how to choose among these agents and how to sequence them. Other areas with active investigation include identifying predictive biomarkers for the selection of patients whom may benefit more from CDK4/6 inhibitors, deciding whether to continue CDK4/6 inhibitors after disease progression on CDK4/6 inhibitors, creating novel treatment combinations and expanding use beyond HR+/HER2- MBC. Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR+/HER2- MBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available